CDK3, CDK5 and CDK8 Proteins as Prognostic and Potential Biomarkers in Colorectal Cancer Patients

被引:16
|
作者
Wang, Dan [1 ]
Zhou, Yanhong [2 ]
Hua, Li [2 ]
Li, Jiaxiang [2 ]
Zhu, Ni [2 ]
Liu, Yifei [2 ]
机构
[1] Hubei Univ Sci & Technol, Xianning Med Coll, Sch Pharm, Xianning, Hubei, Peoples R China
[2] Hubei Univ Sci & Technol, Xianning Med Coll, Sch Stomatol & Ophthalmol, Xianning, Hubei, Peoples R China
关键词
colorectal cancer; cyclin-dependent kinases family; mRNA expression; prognosis; risk score model; WEB SERVER; INHIBITORS; EXPRESSION;
D O I
10.2147/IJGM.S349576
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: In the cell cycle, cyclin-dependent kinases (CDKs) play a positive regulatory role, which is essential for normal cell growth, but the expression pattern and prognostic significance of the CDK family in colorectal cancer (CRC) have not been systematically investigated. Methods: In our study, we analyzed and visualized the expression of CDKs in CRC using TCGA, GEPIA, GSCALite, TIMER, HPA database, and R language CDKs risk model was constructed. Results: Overall, CDKs (CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7 and CDK8) were differentially expressed between normal controls and colorectal cancer. Three CDKs genes (CDK3, CDK5 and CDK8) associated with prognosis were obtained by univariate and multivariate Cox and LASSO regression analysis. In CRC, CDK3, CDK5 and CDK8 are significantly associated with expression levels of recognized immune infiltrates. Conclusion: CDK3, CDK5 and CDK8 are potential diagnostic markers for CRC; meanwhile, CDK3, CDK5 and CDK8 are potential prognostic markers for CRC; studying the relationship between CDKs and tumor immunology may be helpful for immunotherapy of CRC, and more studies are needed to confirm these results.
引用
收藏
页码:2233 / 2245
页数:13
相关论文
共 50 条
  • [21] Biomarker Discovery for Cancer Sensitivity to CDK8 Inhibitors
    Lu, Zhixin
    Spear, Jensen E.
    Russu, Wade A.
    FASEB JOURNAL, 2018, 32 (01):
  • [22] Elucidation of the different roles of CDK8 and CDK19 in colorectal cancer (CRC) using CRISPR gene editing technology
    Ruiz, Maria J. Ortiz
    Popoola, Olajumoke
    Mallinger, Aurelie
    Gowan, Sharon
    Court, Will
    Box, Gary
    Valenti, Melanie
    Brandon, Alexis De Haven
    Te-Poele, Robert
    Workman, Paul
    Schiemann, Kai
    Esdar, Cristina
    Wienke, Dirk
    Blagg, Julian
    Clarke, Paul
    Eccles, Suzanne A.
    CANCER RESEARCH, 2016, 76
  • [23] Role of CDK8 in colon cancer hepatic metastasis
    Liang, Jiaxin
    Chen, Mengqian
    Karthikeyan, Mythreye
    Pena, M. Marjorette
    Hughes, Daniel
    Kaza, Vimala
    Lim, Chang-Uk
    Broude, Eugenia
    Roninson, Igor B.
    CANCER RESEARCH, 2017, 77
  • [24] The Role of Cdk5 in Neuroendocrine Thyroid Cancer
    Pozo, Karine
    Castro-Rivera, Emely
    Tan, Chunfeng
    Plattner, Florian
    Schwach, Gert
    Siegl, Veronika
    Meyer, Douglas
    Guo, Ailan
    Gundara, Justin
    Mettlach, Gabriel
    Richer, Edmond
    Guevara, Jonathan A.
    Ning, Li
    Gupta, Anjali
    Hao, Guiyang
    Tsai, Li-Huei
    Sun, Xiankai
    Antich, Pietro
    Sidhu, Stanley
    Robinson, Bruce G.
    Chen, Herbert
    Nwariaku, Fiemu E.
    Pfragner, Roswitha
    Richardson, James A.
    Bibb, James A.
    CANCER CELL, 2013, 24 (04) : 499 - 511
  • [25] Association of neurofilament proteins with neuronal Cdk5 activator
    Qi, Z
    Tang, DM
    Zhu, XD
    Fujita, DJ
    Wang, JH
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (04) : 2329 - 2335
  • [26] CDK8/19 inhibitors: 3-benzylindazoles
    Schiemann, Kai
    Mallinger, Aurelie
    Wienke, Dirk
    Esdar, Christina
    Poeschke, Oliver
    Busch, Michael
    Rohdich, Felix
    Eccles, Suzanne
    Schneider, Richard
    Raynaud, Florence
    Czodrowski, Paul
    Musil, Djordje
    Schwarz, Daniel
    Urbahns, Klaus
    Blagg, Julian
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
  • [27] Characterization of the Mediator complex subunits CDK8 and CDK19 during prostate cancer progression
    Offermann, Anne
    Becker, Finn
    Joerg, Vincent
    Hupe, Marie Christine
    Braegelmann, Johannes
    Merseburger, Axel
    Sailer, Verena
    Perner, Sven
    LABORATORY INVESTIGATION, 2019, 99
  • [28] Characterization of the Mediator complex subunits CDK8 and CDK19 during prostate cancer progression
    Offermann, Anne
    Becker, Finn
    Joerg, Vincent
    Hupe, Marie Christine
    Bragelmann, Johannes
    Merseburger, Axel
    Sailer, Verena
    Perner, Sven
    MODERN PATHOLOGY, 2019, 32
  • [29] Targeting mediator subunits CDK8/CDK19 for treatment of advanced prostate cancer.
    Hupe, Marie C.
    Offermann, Anne
    Becker, Finn
    Joerg, Vincent
    Vogel, Wenzel
    Braegelmann, Johannes
    Perner, Sven
    Merseburger, Axel Stuart
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [30] CDK8 protein complex as a potential biomarker and therapeutic target in breast cancer
    McDermott, M. S. J.
    Gyorffy, B.
    Chumanevich, A. A.
    Kaza, V.
    Porter, D. C.
    Catroppo, J. F.
    Chen, M.
    Oliver, D.
    Shtutman, M.
    Roninson, I. B.
    Broude, E. V.
    CANCER RESEARCH, 2016, 76